UK Markets closed

Bionano Genomics, Inc. (0A4K.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.3700-0.0695 (-4.83%)
At close: 02:49PM BST

Bionano Genomics, Inc.

9540 Towne Centre Drive
Suite 100
San Diego, CA 92121
United States
858 888 7600
https://www.bionanogenomics.com

Sector(s)
Industry
Full-time employees299

Key executives

NameTitlePayExercisedYear born
Dr. Robert Erik Holmlin M.B.A., Ph.D.Pres, CEO, Sec. & Director660.84kN/A1968
Mr. Mark OldakowskiChief Operating Officer487.73kN/A1974
Mr. Richard ShippyChief Bus. Officer & Head of Global Sales321.72kN/A1971
Mr. Christopher P. StewartChief Financial OfficerN/AN/A1970
Ms. Helene KleinChief People OfficerN/AN/AN/A
Dr. Alka Chaubey FACMG, Ph.D.Chief Medical OfficerN/AN/A1973
Dr. Soheil Shams Ph.D.Chief Informatics OfficerN/AN/A1965
Mark AdamchakControllerN/AN/AN/A
Dr. Paul R. Selvin Ph.D.Scientific AdvisorN/AN/AN/A
Prof. Pui-Yan Kwok M.D., Ph.D.Scientific AdvisorN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Corporate governance

Bionano Genomics, Inc.’s ISS governance QualityScore as of 1 July 2022 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.